Early-initiated High Flow Oxygen Therapy vs Conventional Oxygen Therapy Among Patients With ARDS in the Course of SARS-CoV2 Pneumonia.

NCT05197686 — Not applicable, Unknown, 100 participants, Pomeranian Medical University Szczecin

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Early-initiated High Flow Oxygen Therapy vs Conventional Oxygen Therapy Among Patients With ARDS in the Course of SARS-CoV2 Pneumonia: Prognosis and Impact on the Respiratory and Cardiovascular Systems.

RegistryNCT05197686
StatusUnknown
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: single, treatment
Enrollment100 (Estimated)
SponsorPomeranian Medical University Szczecin (Other)
ConditionsCorona Virus Infection, ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2, Oxygen Deficiency
InterventionsOxygen theraphy with high flow nasal cannule, Oxygen theraphy with mask with reservoir (Device)
Datesstart 2022-01-18 (estimated), primary completion 2022-06-30 (estimated), completion 2022-12-31 (estimated), first posted 2022-01-19, last updated 2022-01-19
Locations1 site in Poland

Related Papers Related Patents Related Grants Related Experts
All trials for Corona Virus Infection All trials for ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 All trials of Oxygen theraphy with high flow nasal cannule All trials of Oxygen theraphy with mask with reservoir

-Summary

The aim of the study is to compare two methods of oxygen therapy in patients with acute respiratory distress syndrome in the course of SARS-CoV2 pneumonia. The initial method of oxygen supply during coronavirus pneumonia is conventional oxygen therapy using a face mask or nasal cannula. However, there have been reports in the literature that early initiation of high-flow oxygen therapy with a nasal cannula is associated with better prognosis. The study we perform is intended to provide reliable evidence for confirmation this hypothesis.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
HFNCExperimentalDevice: Oxygen theraphy with high flow nasal cannule
COTActive comparatorDevice: Oxygen theraphy with mask with reservoir
  • Oxygen theraphy with high flow nasal cannule (Device): Oxygen theraphy with high flow nasal cannule
  • Oxygen theraphy with mask with reservoir (Device): Oxygen theraphy with mask with reservoir

+Outcome measures

Primary outcomes

  • Lower mortality in HFNC group [6 months]
  • Lower percent of intubation in HFNC group [6 months]
  • Shorter time of hospitalization in HFNC group [6 months]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

1. The diagnosis of a current SARS-CoV2 infection (confirmed RT-PCR test or antigen test \[allowed in Poland, with sensitivity ≥90 and specificity ≥97\]);
2. Hospitalization in the Oxygen Sector of the Temporary Hospital in Szczecin;
3. Pneumonia during SARS-CoV2 infection;
4. ARDS (PaO 2 / FiO 2 ratio ≤300);
5. Oxygen flow 8-12 l / min on mask with reservoir and ≤ 60 mmHg paO2 and / or SpO2 < 92%;
6. TNo current indications for treatment in the ICU;
7. Permisson of the patient.

Exclusion Criteria:

1. Probable lack of cooperation with patient;
2. Severe Disease disease, eg generalized neoplastic disease;
3. Concomitant pulmonary diseases (eg, fibrosis lungs);
4. Respiratory acidosis - pH <7.3 with pCO2> 50 mmHg;
5. Disturbances of consciousness - GCS < 12;

+Locations (1)

FacilityCityCountryStatus
Oxygen Therapy Sector of Temporary HospitalSzczecin, West Pomeranian VoivodeshipPoland

+Publications

  • Baker KF, Hanrath AT, Schim van der Loeff I, Kay LJ, Back J, Duncan CJ. National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. Clin Med (Lond). 2021 Mar;21(2):84-89. doi: 10.7861/clinmed.2020-0688. Epub 2021 Feb 5. PMID 33547065
  • Sayan I, Altinay M, Cinar AS, Turk HS, Peker N, Sahin K, Coskun N, Demir GD. Impact of HFNC application on mortality and intensive care length of stay in acute respiratory failure secondary to COVID-19 pneumonia. Heart Lung. 2021 May-Jun;50(3):425-429. doi: 10.1016/j.hrtlng.2021.02.009. Epub 2021 Feb 10. PMID 33621840
  • Xu Q, Wang T, Qin X, Jie Y, Zha L, Lu W. Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19: a case series. Crit Care. 2020 May 24;24(1):250. doi: 10.1186/s13054-020-02991-7. No abstract available. PMID 32448330
  • Vianello A, Arcaro G, Molena B, Turato C, Sukthi A, Guarnieri G, Lugato F, Senna G, Navalesi P. High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. Thorax. 2020 Nov;75(11):998-1000. doi: 10.1136/thoraxjnl-2020-214993. Epub 2020 Jul 23. PMID 32703883
  • Rorat M, Szymanski W, Jurek T, Karczewski M, Zelig J, Simon K. When Conventional Oxygen Therapy Fails-The Effectiveness of High-Flow Nasal Oxygen Therapy in Patients with Respiratory Failure in the Course of COVID-19. J Clin Med. 2021 Oct 16;10(20):4751. doi: 10.3390/jcm10204751. PMID 34682874